1779 — LongBio Pharma (Suzhou) Income Statement
0.000.00%
Last trade - 00:00- HK$4.53bn
- HK$3.52bn
Annual income statement for LongBio Pharma (Suzhou), fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2024 December 31st | 2025 December 31st | |
|---|---|---|
| Period Length: | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS |
| Standards: | IFRS | IFRS |
| Status: | Final | Final |
| Total Revenue | 0 | 0 |
| Selling / General / Administrative Expenses | ||
| Research And Development | ||
| Operating Interest Expense / Income | ||
| Other Operating Expenses | ||
| Total Operating Expenses | 106 | 159 |
| Operating Profit | -106 | -159 |
| Total Net Non Operating Interest Income / Expense | ||
| Total Net Non Operating Interest Income / Expense | ||
| Net Income Before Taxes | -137 | -176 |
| Provision for Income Taxes | ||
| Net Income After Taxes | -137 | -176 |
| Net Income Before Extraordinary Items | ||
| Net Income | -137 | -176 |
| Income Available to Common Shareholders Excluding Extraordinary Items | ||
| Income Available to Common Shareholders Including Extraordinary Items | ||
| Diluted Net Income | -137 | -176 |
| Diluted Weighted Average Shares | ||
| Basic EPS Including Extraordinary Items | ||
| Diluted EPS Including Extraordinary Items | ||
| Diluted EPS Excluding Extraordinary Items | ||
| Normalised Income Before Taxes | ||
| Normalised Income After Taxes | ||
| Normalised Income Available to Common Shareholders | ||
| Diluted Normalised EPS | -1.82 | -2.15 |